Eligibility Criteria
Patients were included in the study if they fulfilled all of the
following eligibility criteria: (1) adult patients aged ≥18 years, but ≤
75 years; (2) diagnosed with ACS (STEMI, NSTEMI, or UA); (3) were either
statin-naïve or on a low-to-moderate intensity statin therapy prior to
admission and; (4) were discharged on either atorvastatin 40mg or
atorvastatin 80mg. Patients were excluded if they had one of the
following: (1) a known hypersensitivity to any statin; (2) active liver
disease or hepatic dysfunction defined as a level of alanine
aminotransferase (ALT) or aspartate aminotransferase (AST) of
> three times ULN; (3) pregnancy or breast-feeding; (4)
receiving proprotein convertase subtilisin/kexin Type 9 (PCSK9)
inhibitor; (5) receiving ezetimibe; (6) or already on a high-intensity
statin prior to ACS diagnosis and hospitalization.